





When one thinks of FDA’s Office of Prescription Drug Promotion (OPDP) there is a likely tendency to think of the regulatory action letters – Warning Letters or Untitled Letters -issued by that office to pharmaceutical companies about their promotional communications. … Continue reading
This week a large number of people and entities released their presentations that will be given at the FDA Part 15 Meeting on Social Media and Medical Product Promotion to be held Thursday and Friday, November 12 and 13th at … Continue reading